In vivo CAR-T Program

About Deliver Biosciences

Deliver Biosciences is a private, pre-clinical stage biotech founded in 2021, pioneering a targeted nanoparticle platform for in vivo cell and gene therapy. The technology is designed to deliver diverse genetic payloads (e.g., DNA, mRNA for CARs) directly to specific cell types within the body, potentially bypassing the complex and costly ex vivo manufacturing of current cell therapies. Led by a scientifically strong founding team and advised by industry veterans, the company's first program targets the creation of in vivo CAR-T cells for oncology, aiming to democratize access to these potent treatments. Its platform approach holds promise for a broad range of serious diseases currently lacking curative options.

About Hone Bio

Hone Bio is a VC-backed, pre-clinical biotech tackling a fundamental limitation in lipid nanoparticle (LNP) drug delivery: inherent liver accumulation. The company's proprietary NanoPilot technology is a membrane-anchored antibody platform that actively blocks liver uptake while simultaneously directing LNPs to desired target cells via a modular targeting domain. This dual-function technology, which can be applied to standard LNPs in a simple 10-minute process, has the potential to expand the therapeutic application of mRNA, DNA, and other nucleic acid payloads to treat diseases in tissues like the lungs, brain, and immune cells. Hone Bio is part of the Science Creates ecosystem in Bristol and is advancing its platform through preclinical validation.

Therapeutic Areas

Other Cancer Immunotherapy Drugs